Key facts
- Memgen’s last known valuation is $98.1M (Jun 2023).
- It has raised $36.9M across 6 recorded rounds; the latest was Seed Round ($950K) in Nov 2024.
- Notable investors include University of California, San Diego.
- Memgen has filed 10 Form Ds with the SEC since 2018, most recently Dec 2024 ($950K sold to 2 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Memgen
Funding rounds
6 roundsAbout Memgen
Developer of viral immunotherapies designed to treat multiple cancer types. The company develops clinical-stage therapies using viral vectors to activate dendritic cells and induce anti-tumor immune responses, enabling patients with cancers like bladder, melanoma, lymphoma, lung, and liver to overcome resistance to chemotherapy.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2004
- Employees
- 7
- Website
- memgenbio.com/
- Ownership
- Privately Held (backing)
Memgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Memgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Memgen in its N-PORT filings yet. We sweep new filings monthly.